Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
![US FDA, drug shortage, Cisplatin, pharma manufacturers](https://pharmtales.com/wp-content/uploads/2023/09/White-House-reports-progress-on-easing-cancer-drug-shortages-with-FDA-manufacturers.jpg)
White House reports progress on easing cancer drug shortages with FDA, manufacturers
The US FDA and pharmaceutical manufacturers are making significant strides in addressing the nationwide shortage of popular cancer drugs, as ...
![Astellas pharma, drug manufacturing, Manufacturing Facilities, Contract Development and Manufacturing Organization](https://pharmtales.com/wp-content/uploads/2023/09/Astellas-to-invest-354M-in-new-Irish-plant-for-antibody-drugs.jpg)
Astellas to invest $354M in new Irish plant for antibody drugs
Astellas is strengthening its significant presence in Ireland with a substantial investment of 330 million euros ($354 million) in a ...
![Sanofi, drug repurposing, First Wave BioPharma, Alzheimer's disease, urinary incontinence, Capeserod](https://pharmtales.com/wp-content/uploads/2023/09/First-Wave-acquires-Sanofis-Alzheimers-drug-for-GI-disorders-retains-buyback-option.jpg)
First Wave acquires Sanofiâs Alzheimerâs drug for GI disorders, retains buyback option
First Wave BioPharma has seized an opportunity from Sanofi to revive a long-dormant molecule, capeserod, by paying an upfront sum ...
![Hemogenyx Pharmaceuticals, Cell & Gene Therapy, clinical hold, CAR-T](https://pharmtales.com/wp-content/uploads/2023/09/Hemogenyx-clears-FDA-hurdle-for-its-novel-CAR-T-therapy-for-AML.jpg)
Hemogenyx clears FDA hurdle for its novel CAR-T therapy for AML
Hemogenyx Pharmaceuticals has moved a step closer to advancing its CAR-T therapy, HEMO-CAR-T, into clinical trials following the FDA’s acceptance ...
![Rocket Pharmaceuticals, FDA, gene therapy, Danon disease, trial design, stock price, RP-A501](https://pharmtales.com/wp-content/uploads/2023/09/Rocket-Pharma-gets-FDA-green-light-for-gene-therapy-trial-stock-surges.jpg)
Rocket Pharma gets FDA green light for gene therapy trial, stock surges
Rocket Pharmaceuticals has achieved alignment with the FDA regarding the design of a pivotal phase 2 clinical trial for a ...
![Moderna, mRNA, flu vaccine, phase 3, respiratory viruses, RSV vaccine](https://pharmtales.com/wp-content/uploads/2023/09/Modernas-mRNA-flu-vaccine-shows-phase-3-success-plans-for-combo-shots-by-2025.jpg)
Modernaâs mRNA flu vaccine shows phase 3 success, plans for combo shots by 2025
Moderna has achieved significant progress in its quest to develop an mRNA flu vaccine, with the updated mRNA-1010 version successfully ...
![Eiger BioPharmaceuticals, hepatitis, lonafarnib, liver toxicity, phase 3 trial hold, pipeline, Clinical trial hold](https://pharmtales.com/wp-content/uploads/2023/09/Eiger-halts-hepatitis-drug-development-after-liver-toxicity-seeks-funding-for-other-programs.jpg)
Eiger halts hepatitis drug development after liver toxicity, seeks funding for other programs
Eiger BioPharmaceuticals has made the decision to discontinue the pursuit of a home for peginterferon lambda, a drug that was ...
![BioMarin, Rare disease, pipeline update, Roctavian, gene therapy, hemophilia A, Pipeline addition](https://pharmtales.com/wp-content/uploads/2023/09/BioMarin-RD-chief-reveals-two-new-pipeline-candidates-and-strategy-to-sustain-innovation.jpg)
BioMarin R&D chief reveals two new pipeline candidates and strategy to sustain innovation
BioMarin, the California-based biotech giant, is embarking on a mission to create its most robust pipeline in history, with a ...
![Calidi Biotherapeutics, SPAC, cell therapy, allogeneic, off-the-shelf treatment, Special purpose acquisition company, M&A](https://pharmtales.com/wp-content/uploads/2023/09/Calidi-Biotherapeutics-goes-public-through-SPAC-deal-to-advance-off-the-shelf-cancer-treatments.jpg)
Calidi Biotherapeutics goes public through SPAC deal to advance off-the-shelf cancer treatments
Calidi Biotherapeutics, a San Diego-based biotech, has chosen the special purpose acquisition company (SPAC) path to enter the public market, ...
![Phesi, Krystelis, clinical trial, Collaboration, data analytics, Diversity in clinical trial](https://pharmtales.com/wp-content/uploads/2023/09/Phesi-partners-with-Krystelis-to-boost-diversity-in-clinical-trials.jpg)
Phesi partners with Krystelis to boost diversity in clinical trials
Clinical research and analytics specialist Phesi, in collaboration with Krystelis, has introduced a groundbreaking service aimed at enhancing the diversity ...
![Madrigal Pharmaceuticals, NASH, resmetirom, FDA, priority review, nonalcoholic steatohepatitis](https://pharmtales.com/wp-content/uploads/2023/09/Madrigals-NASH-drug-gets-fast-track-review-from-FDA-no-panel-needed.jpg)
Madrigalâs NASH drug gets fast-track review from FDA, no panel needed
In the wake of a recent CEO transition, Madrigal Pharmaceuticals has disclosed that its nonalcoholic steatohepatitis (NASH) drug has been ...
![FDA, eye drugs, warning letters, online drug seller, misbranded, unapproved drugs, ophthalmology](https://pharmtales.com/wp-content/uploads/2023/09/FDA-cracks-down-on-8-firms-selling-illegal-eye-drugs-online.jpg)
FDA cracks down on 8 firms selling illegal eye drugs online
In a recent development, eight companies have come under scrutiny for allegedly producing unauthorized eye medications, according to the FDA’s ...
![Sanofi, Ice-T, flu shot, vaccine,Video campaign, Flu season](https://pharmtales.com/wp-content/uploads/2023/09/Sanofi-teams-up-with-Ice-T-to-scare-people-into-getting-flu-shots.jpg)
Sanofi teams up with Ice-T to scare people into getting flu shots
Sanofi is breaking the mold with a bold and captivating campaign aimed at alerting older adults to the perils of ...
![Orchid Pharma, GSK, Shionogi, cefiderocol, antibiotic, license, global access](https://pharmtales.com/wp-content/uploads/2023/09/Orchid-Pharma-to-produce-GSK-and-Shionogis-antibiotic-for-global-access.jpg)
Orchid Pharma to produce GSK and Shionogiâs antibiotic for global access
Orchid Pharma, a subsidiary of India’s Dhanuka Labs, has secured a sublicense to manufacture the antibiotic cefiderocol. This development is ...
![Safecor, FDA inspection, drug repackaging, warning letter, Ohio, quality, safety issues, violation](https://pharmtales.com/wp-content/uploads/2023/09/FDA-warns-Ohio-company-for-serious-violations-in-drug-repackaging-process.jpg)
FDA warns Ohio company for serious violations in drug repackaging process
Ohio-based pharmaceutical repackaging company, Safecor Health, finds itself in the FDA’s crosshairs as it receives a stern warning letter highlighting ...
![HHS, Merck, Medicare, drug price, negotiation, lawsuit, IRA, Department of Health and Human Services](https://pharmtales.com/wp-content/uploads/2023/09/HHS-says-Merck-cant-sue-over-Medicare-drug-price-talks.jpg)
HHS says Merck canât sue over Medicare drug price talks
Merck & Co., a prominent pharmaceutical company, led the charge in challenging the contentious Medicare price negotiation provisions outlined in ...
![Moderna, COVID-19 booster, vaccine, low demand, manufacturing](https://pharmtales.com/wp-content/uploads/2023/09/Moderna-to-cut-down-COVID-booster-production-amid-low-demand-Reuters-reports.jpg)
Moderna to cut down COVID booster production amid low demand: Reuters reports
While the FDA and the Centers for Disease Control and Prevention (CDC) have given their green light to updated COVID ...
![Ferring, Adstiladrin, Gene therapy, bladder cancer, FDA, early experience program](https://pharmtales.com/wp-content/uploads/2023/09/Ferring-launches-bladder-cancer-gene-therapy-Adstiladrin-in-US-through-early-experience-program.jpg)
Ferring launches bladder cancer gene therapy Adstiladrin in US through early experience program
Ferring Pharmaceuticals achieved a significant milestone by administering its groundbreaking gene therapy, Adstiladrin, to its first commercial patient. This innovative ...
![Phenylephrine, Decongestant, FDA, cold medicine, Sudafed, Dayquil, OTC drug Image: pharmacies](https://pharmtales.com/wp-content/uploads/2023/09/FDA-panel-votes-against-phenylephrine-a-common-decongestant-drug-in-many-cold-medicines.jpg)
FDA panel votes against phenylephrine, a common decongestant drug in many cold medicines
For decades, the shelves of American pharmacies have been stocked with hundreds of oral decongestant products containing phenylephrine, promising relief ...
![CureVac, mRNA influenza vaccine, mRNA vaccine, GSK, mRNA techÂnology platform](https://pharmtales.com/wp-content/uploads/2023/09/CureVac-selects-mRNA-flu-vaccine-candidate-for-GSK-collaboration-but-data-remains-secret.jpg)
CureVac selects mRNA flu vaccine candidate for GSK collaboration, but data remains secret
CureVac, the renowned biotech company, has made a significant stride in its quest to develop an mRNA influenza vaccine. While ...
![Neurocrine Biosciences, elagolix, hyperplasia, phase 3 trial data, FDA, uterine cancer, congenital adrenal hyperplasia](https://pharmtales.com/wp-content/uploads/2023/09/Neurocrine-advances-potential-blockbuster-drug-for-endometrial-hyperplasia-after-phase-3-success.jpg)
Neurocrine advances potential blockbuster drug for endometrial hyperplasia after phase 3 success
Neurocrine Biosciences is banking on its hyperplasia drug, crinecerfont, which analysts predict could be a blockbuster. The company has been ...
![Exelixis, Insilico Medicine, LIB Therapeutics, licensing deal, artificial intelligence, ISM3091](https://pharmtales.com/wp-content/uploads/2023/09/Exelixis-partners-with-AI-company-Insilico-to-discover-new-drugs-LIB-sells-China-rights-for-PCSK9-drug.jpg)
Exelixis partners with AI company Insilico to discover new drugs, LIB sells China rights for PCSK9 drug
Exelixis, the pharmaceutical company recognized for its solid tumor medication Cabometyx, is adopting artificial intelligence (AI) to bolster its pipeline. ...
![CDC, flu vaccine, Awareness campaign, vaccines, Seasonal flu vaccine](https://pharmtales.com/wp-content/uploads/2023/09/CDC-launches-âWild-to-Mild-campaign-to-boost-flu-vaccination-rates-among-high-risk-groups.jpg)
CDC launches âWild to Mildâ campaign to boost flu vaccination rates among high-risk groups
The CDC is embarking on an ambitious mission to reframe perceptions of flu vaccines as a response to declining vaccination ...
![AbbVie, Skyrizi, Stelara , Johnson & Johnson, Crohnâs disease](https://pharmtales.com/wp-content/uploads/2023/09/AbbVies-Skyrizi-beats-JJs-Stelara-in-Crohns-disease-showdown.jpg)
AbbVieâs Skyrizi beats J&Jâs Stelara in Crohnâs disease showdown
AbbVie’s revolutionary anti-inflammatory medication, Skyrizi, has been consistently outperforming its competitors in recent clinical trials, making waves in the field ...
![Bristol Myers Squibb, cycling, cancer, donation, V Foundation for Cancer Research](https://pharmtales.com/wp-content/uploads/2023/09/Bristol-Myers-Squibb-celebrates-10-years-of-cycling-for-cancer-with-a-cross-country-ride-and-a-1.5M-donation.jpg)
Bristol Myers Squibb celebrates 10 years of cycling for cancer with a cross-country ride and a $1.5M donation
Bristol Myers Squibb is commemorating a decade of charitable efforts by organizing a 3,000-mile bike ride to support cancer patients. ...
![Xspray Pharma, Sprycel, patent, lawsuit, Sprycel generic, chronic myeloid leukemia, acute lymphatic leukemia, Bristol Myers Squibb](https://pharmtales.com/wp-content/uploads/2023/09/Xspray-Pharma-settles-with-BMS-over-Sprycel-generic-awaits-FDA-nod.jpg)
Xspray Pharma settles with BMS over Sprycel generic, awaits FDA nod
Xspray Pharma, which encountered an FDA setback in July, was initially aiming to launch its competitor to Bristol Myers Squibb’s ...
![Novartis, drug recall, voluntary recall, contamination, Sandimmune, immunosuppressant, crystal formation](https://pharmtales.com/wp-content/uploads/2023/09/Novartis-recalls-lot-of-Sandimmune-due-to-crystal-formation-in-oral-solution.jpg)
Novartis recalls lot of Sandimmune due to crystal formation in oral solution
Novartis is taking action to recall one lot of its immunosuppressant medication, Sandimmune, due to an unexpected issue with crystallization ...